Amgen To File Panitumumab In Second-Half 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Application will seek approval for third-line treatment of colorectal cancer. Amgen says the anti-EGRF monoclonal antibody shows fewer adverse reactions than Bristol-Myers Squibb/Imclone's Erbitux.You may also be interested in...
Amgen Raises Profile Of Oncology Therapeutics Unit
Amgen Raises Profile Of Oncology Therapeutics Unit
Phase III Enrollment For Amgen's Panitumumab Slowed By Erbitux Approval
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: